Aronorabio
Portland, US · Founded 2009 · 11 employees on LinkedIn · 1 known investors
Aronora is a clinical-stage biotech developing antithrombotic therapies, including factor XI/XIa inhibitors and thrombolytic drug candidates, to treat and manage thrombotic and thromboembolic conditions such as acute ischemic stroke, heart attack, and pulmonary embolism. Its pipeline of cardio-hematology programs targets patients requiring time-sensitive thrombolytic intervention or management of thrombosis risk.
Founders & leadership
Aronorabio was founded in 2009 by Erik I. Tucker.
EI
Erik I. TuckerinPresident & Chief Executive Officer
Investors · 1
Non-dilutive funding · 23 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $998.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $700.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $301.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $994.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $2.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $2.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $2.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $260.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $315.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $309.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $297.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $457.7K |
| Department of Agriculture (USDA) | Phase I | 2003 | $75K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Aronorabio do?
- Aronora is a clinical-stage biotech developing antithrombotic therapies, including factor XI/XIa inhibitors and thrombolytic drug candidates, to treat and manage thrombotic and thromboembolic conditions such as acute ischemic stroke, heart attack, and pulmonary embolism. Its pipeline of cardio-hematology programs targets patients requiring time-sensitive thrombolytic intervention or management of thrombosis risk.
- Who founded Aronorabio?
- Aronorabio was founded by Erik I. Tucker in 2009.
- Who are Aronorabio's investors?
- Aronorabio's investors include NYBC Ventures.
- Where is Aronorabio headquartered?
- Aronorabio is headquartered in Portland, US.